2016
Chlamydia Peritonitis and Ascites Mimicking Ovarian Cancer
Gojayev A, English DP, Macer M, Azodi M. Chlamydia Peritonitis and Ascites Mimicking Ovarian Cancer. Case Reports In Obstetrics And Gynecology 2016, 2016: 8547173. PMID: 27747116, PMCID: PMC5055912, DOI: 10.1155/2016/8547173.Peer-Reviewed Original ResearchPelvic inflammatory diseaseDiffuse ascitesSerum CA-125 levelsPelvic cystic massRepeat surgical procedureCA-125 levelsPostinflammatory scarringAbdominal painThorough workupOvarian neoplasmsPelvic cystAdhesive diseasePathologic findingsCystic massInflammatory diseasesGynecologic examOvarian cancerInclusion cystsDifferential diagnosisSurgical proceduresInvasive proceduresInfectious agentsAscitesChlamydiaActive females
2009
Peritoneal tuberculosis with elevated serum Ca-125 level mimicking advanced stage ovarian cancer: a case report
Tan O, Luchansky E, Rosenman S, Pua T, Azodi M. Peritoneal tuberculosis with elevated serum Ca-125 level mimicking advanced stage ovarian cancer: a case report. Archives Of Gynecology And Obstetrics 2009, 280: 333-335. PMID: 19184073, DOI: 10.1007/s00404-009-0946-y.Peer-Reviewed Original ResearchConceptsSerum CA-125 levelsCA-125 levelsPeritoneal tuberculosisCA 125Elevated serum CA 125 levelsAdvanced stage ovarian cancerElevated serum CA 125Unnecessary extensive surgerySerum CA 125Resolution of symptomsFrozen section evaluationStage ovarian cancerAcid-fast stainOmental cakingAbdominal distentionExtrapulmonary diseaseNight sweatsDiagnostic laparoscopyCommon presentationExtensive surgeryMultiple granulomasPhysical examinationRadiologic studiesCase reportOvarian cancer
2005
Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma
O'Malley DM, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M, Schwartz P, Rutherford T. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecologic Oncology 2005, 98: 242-248. PMID: 15992916, DOI: 10.1016/j.ygyno.2005.04.032.Peer-Reviewed Original ResearchConceptsRecurrent ovarian cancerWeekly topotecanOvarian cancerHematologic toxicityPartial responseGrade 3 hematologic toxicityRecurrent epithelial ovarian carcinomaSerial CA-125 measurementsRecurrent epithelial ovarian cancerSerial CA-125 levelsCycles of topotecanGrade 4 toxicityPlatinum-refractory diseaseCA-125 levelsRecords of patientsAppropriate treatment optionsCA-125 measurementEpithelial ovarian cancerEpithelial ovarian carcinomaNonhematologic toxicityStable diseasePrior regimenRefractory diseaseImproved tolerabilityMedian age